Yin yang 1 expression in human tumors

Cell Cycle

Volumn 9, Issue 3, 2010, Pages 512-522

  Zaravinos, Apostolos ^a   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Computational analysis; Datasets; Human tumors; Prognostic factor; Transcription factor; Tumor progression; Yin yang 1

Indexed keywords

TRANSCRIPTION FACTOR YY1;

AUTOREGULATION; BINDING SITE; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; COLON CANCER; CONTROLLED STUDY; ENZYME REGULATION; GENE OVEREXPRESSION; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; MOLECULAR INTERACTION; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SKIN CANCER; THYROID CANCER; UTERINE CERVIX CANCER; ARTICLE; BIOLOGICAL MODEL; CHEMISTRY; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; YY1 TRANSCRIPTION FACTOR;

EID: 77951881687     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.3.10588     Document Type: Review

References (79)

1. Shi Y, Lee JS, Galvin KM. Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta 1997; 1332:22-5. (Pubitemid 27211616)
2. Thomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene 1999; 236:197-208.
3. Chang LS, Shi Y, Shenk T. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J Virol 1989; 63:3479-88. (Pubitemid 19181410)
4. Shi Y, Seto E, Chang LS, et al. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell 1991; 67:377-88. (Pubitemid 121001453)
5. Gordon S, Akopyan G, Garban H, et al. Transcription factor YY1: structure, function and therapeutic implications in cancer biology. Oncogene 2006; 25:1125-42. (Pubitemid 43297928)
6. Schug J, Schuller WP, Kappen C, et al. Promoter features related to tissue specificity as measured by Shannon entropy. Genome Biol 2005; 6:33.
7. Calame K, Atchison M. YY1 helps to bring loose ends together. Genes Dev 2007; 21:1145-52. (Pubitemid 46789871)
8. He Y, Casaccia-Bonnefil P. The Yin and Yang of YY1 in the nervous system. J Neurochem 2008; 106:1493-502.
9. 1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 2004; 24:7260-74.
10. Yakovleva T, Kolesnikova L, Vukojevic V, et al. YY1 binding to a subset of p53 DNA-target sites regulates p53-dependent transcription. Biochem Biophys Res Commun 2004; 318:615-24. (Pubitemid 38559074)
11. Sui G, Affar el B, Shi Y, et al. Yin Yang 1 is a negative regulator of p53. Cell 2004; 117:859-72.
12. Gronroos E, Terentiev AA, Punga T, et al. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci USA 2004; 101:12165-70. (Pubitemid 39145414)
13. Nayak BK, Das BR. Differential binding of NF1 transcription factor to p53 gene promoter and its depletion in human breast tumours. Mol Biol Rep 1999; 26:223-30.
14. Riggs KJ, Saleque S, Wong KK, et al. Yin-yang 1 activates the c-myc promoter. Mol Cell Biol 1993; 13:7487-95.
15. Shrivastava A, Yu J, Artandi S, et al. YY1 and c-Myc associate in vivo in a manner that depends on c-Myc levels. Proc Natl Acad Sci USA 1996; 93:10638-41. (Pubitemid 26333040)
16. Austen M, Cerni C, Luscher-Firzlaff JM, et al. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc. Oncogene 1998; 17:511-20. (Pubitemid 28395916)
17. Kim JD, Yu S, Kim J. YY1 is autoregulated through its own DNA-binding sites. BMC Mol Biol 2009; 10:85.
18. Gashaw I, Grummer R, Klein-Hitpass L, et al. Gene signatures of testicular seminoma with emphasis on expression of ets variant gene 4. Cell Mol Life Sci 2005; 62:2359-68. (Pubitemid 41500551)
19. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 2009; 27:2503-8.
20. Skotheim RI, Lind GE, Monni O, et al. Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res 2005; 65:5588-98. (Pubitemid 40911159)
21. Chandran UR, Ma C, Dhir R, et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7:64. (Pubitemid 47161402)
22. Nanni S, Priolo C, Grasselli A, et al. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res 2006; 4:79-92.
23. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8:393-406. (Pubitemid 41579834)
24. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1:203-9. (Pubitemid 41039166)
25. Vanaja DK, Cheville JC, Iturria SJ, et al. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63:3877-82.
26. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001; 98:1176-81.
27. Hendrix ND, Wu R, Kuick R, et al. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 2006; 66:1354-62. (Pubitemid 43259914)
28. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006; 9:121-32. (Pubitemid 43202662)
29. Turashvili G, Bouchal J, Baumforth K, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007; 7:55.
30. Notterman DA, Alon U, Sierk AJ, et al. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma and normal tissue examined by oligonucleotide arrays. Cancer Res 2001; 61:3124-30.
31. Chen X, Cheung ST, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002; 13:1929-39.
32. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9:416-23.
33. Xie XW, Mei MH, Liao WJ, et al. Expression of CIITA-related MHCII molecules in tumors linked to prognosis in hepatocellular carcinoma. Int J Oncol 2009; 34:681-8.
34. Stearman RS, Dwyer-Nield L, Zerbe L, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005; 167:1763-75.
35. Hoek KS, Schlegel NC, Brafford P, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006; 19:290-302.
36. Andersson A, Ritz C, Lindgren D, et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21:1198-203.
37. Durig J, Bug S, Klein-Hitpass L, et al. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14) (q11q32). Leukemia 2007; 21:2153-63.
38. Diaz-Blanco E, Bruns I, Neumann F, et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 2007; 21:494-504.
39. Gutierrez NC, Lopez-Perez R, Hernandez JM, et al. Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 2005; 19:402-9.
40. Chinnappan D, Xiao D, Ratnasari A, et al. Transcription factor YY1 expression in human gastrointestinal cancer cells. Int J Oncol 2009; 34:1417-23.
41. Tung CS, Mok SC, Tsang YT, et al. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 2009; 22:1243-50.
42. Yoshihara K, Tajima A, Komata D, et al. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci 2009; 100:1421-8.
43. Palmer RD, Barbosa-Morais NL, Gooding EL, et al. Pediatric malignant germ cell tumors show characteristic transcriptome profiles. Cancer Res 2008; 68:4239-47.
44. Hong Y, Ho KS, Eu KW, et al. A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis. Clin Cancer Res 2007; 13:1107-14.
45. Provenzani A, Fronza R, Loreni F, et al. Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis. Carcinogenesis 2006; 27:1323-33.
46. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004; 64:4040-8.
47. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178-86.
48. Wurmbach E, Chen YB, Khitrov G, et al. Genomewide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45:938-47.
49. Wachi S, Yoneda K, Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 2005; 21:4205-8.
50. Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004; 363:775-81.
51. Wrage M, Ruosaari S, Eijk PP, et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res 2009; 15:1566-74.
52. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006; 24:1679-88.
53. Nindl I, Dang C, Forschner T, et al. Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer 2006; 5:30.
54. Talantov D, Mazumder A, Yu JX, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11:7234-42.
55. Stirewalt DL, Meshinchi S, Kopecky KJ, et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 2008; 47:8-20.
56. Wong YF, Selvanayagam ZE, Wei N, et al. Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res 2003; 9:5486-92.
57. Scotto L, Narayan G, Nandula SV, et al. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 2008; 47:755-65.
58. Biewenga P, Buist MR, Moerland PD, et al. Gene expression in early stage cervical cancer. Gynecol Oncol 2008; 108:520-6.
59. Sadikovic B, Yoshimoto M, Chilton-MacNeill S, et al. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet 2009; 18:1962-75.
60. Pilarsky C, Wenzig M, Specht T, et al. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004; 6:744-50.
61. Seligson D, Horvath S, Huerta-Yepez S, et al. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol 2005; 27:131-41.
62. van Leenders GJ, Dukers D, Hessels D, et al. Polycomb-group oncogenes EZH2, BMI1 and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007; 52:455-63.
63. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005; 11:3686-96.
64. Matsumura N, Huang Z, Baba T, et al. Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 2009; 7:210-20.
65. Allouche A, Nolens G, Tancredi A, et al. The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res 2008; 10:9.
66. Lieberthal JG, Kaminsky M, Parkhurst CN, et al. The role of YY1 in reduced HP1alpha gene expression in invasive human breast cancer cells. Breast Cancer Res 2009; 11:42.
67. Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer 2008; 8:394.
68. Baritaki S, Sifakis S, Huerta-Yepez S, et al. Overexpression of VEGF and TGFbeta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol 2007; 31:69-79.
69. de Nigris F, Botti C, de Chiara A, et al. Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer 2006; 42:2420-4.
70. Grubach L, Juhl-Christensen C, Rethmeier A, et al. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol 2008; 81:112-22.
71. Erkeland SJ, Valkhof M, Heijmans-Antonissen C, et al. The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation. Blood 2003; 101:1111-7.
72. Dukers DF, van Galen JC, Giroth C, et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004; 164:873-81.
73. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009; 113:2765-3775.
74. Ruiz-Vela A, Aggarwal M, de la Cueva P, et al. Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways. Blood 2008; 111:1665-76.
75. Sakhinia E, Glennie C, Hoyland JA, et al. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood 2007; 109:3922-8.
76. Dalle S, Dupire S, Brunet-Manquat S, et al. In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res 2009; 15:851-7.
77. Libra M, Castellano G, Baritaki S, et al. Expression, role in transformation and prognostic significance of the transcription factor Yin Yang 1 (YY1) in non-Hodgkin's lymphoma: analyses in NHL tissues by experimental and bioinformatic approaches. Blood (ASH Annual Meeting Abstracts) 2008; 112:2827.
78. Castellano G, Torrisi E, Ligresti G, et al. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 2009; 8:1367-72.
79. Zaravinos A and Spandidos DA. Yin Yang 1 as a prognositc factor. Cell Cycle 2009; 8:1305.